Expert review of anti-infective therapy · 2025
Standard dose could be better! A multicenter study of tigecycline in patients with liver failure.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guo Jinlin, Cai Xinfeng, Wang Shan, Wen Hongping, Ren Jing, Zhou Mi, Li Xingang, Yan Xiaodan, Tian Shuangshuang, Zhang Fang, Liu Yanqin, Zhang Wenjun, Shao Yunyun, Cao Jianghong, Liu Xiaochun, Hou Kaixuan, Wei Dan, Lin Guan
Аннотация
BACKGROUND: High-dose (HD) tigecycline is often required for severe multidrug-resistant gram-negative infections in liver failure patients, despite package recommendations to halve the dose for those with severe liver impairment. This study evaluated the efficacy and safety of different tigecycline doses in this population.
RESEARCH DESIGN AND METHODS: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.
RESULTS: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.
CONCLUSIONS: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.
RESEARCH DESIGN AND METHODS: A retrospective cohort of 192 patients with Child-Pugh grade C liver failure was divided into label-dose (LD), standard-dose (SD), and HD groups. Primary and secondary outcomes included microbial eradication, mortality, and adverse effects.
RESULTS: The SD group achieved higher microbial eradication than LD, with comparable efficacy to HD but fewer adverse events, such as fibrinogen requirements. High-dose treatment increased mortality risk (Hazard Ratio: 1.85, p = 0.062). Optimal microbial eradication and minimized adverse effects occurred with the SD group at 7 days of treatment.
CONCLUSIONS: Standard-dose tigecycline offers a balanced approach to microbial eradication and safety, making it preferable in liver failure patients.